Oral contraceptives and thrombotic diseases: Impact of new epidemiological studies

Oral contraceptives and thrombotic diseases: Impact of new epidemiological studies Oral contraceptives (OCs) are, or perhaps more correctly, were, until recently, being taken by approximately 65 million women worldwide, which corresponds to approximately 6% of all women of reproductive age. OCs have been available since the early 1960s, and there is substantial evidence to suggest that no single medication has had such a profound impact on our reproduction and social life than the pill. In the Scandinavian countries, 30–50% of young women have been reported to be using OCs. Its widespread use throughout the world for several decades indicates that women and their doctors have considered that the benefits of OCs outweigh potential side effects. On October 18, 1995, the Committee on Safety of Medicines in the United Kingdom sent a warning to all British doctors and pharmacists about OCs containing desogestrel or gestodene. A similar warning was subsequently distributed by the German and Norwegian health authorities. As these OC types dominate the market in Northern Europe, many gynaecologists, general practitioners, women of reproductive age, different national bodies on drug safety, and people in general have been asking: • ∗ What was the background for these actions? • ∗ How do we interpret the new studies? • ∗ What do we do now concerning prescription of OCs? • ∗ What is the moral of this story? http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Contraception Elsevier

Oral contraceptives and thrombotic diseases: Impact of new epidemiological studies

Contraception, Volume 53 (3) – Mar 1, 1996

Loading next page...
 
/lp/elsevier/oral-contraceptives-and-thrombotic-diseases-impact-of-new-z7qy1Qeeui
Publisher
Elsevier
Copyright
Copyright © 1996 Elsevier Ltd
ISSN
0010-7824
DOI
10.1016/0010-7824(96)00035-2
Publisher site
See Article on Publisher Site

Abstract

Oral contraceptives (OCs) are, or perhaps more correctly, were, until recently, being taken by approximately 65 million women worldwide, which corresponds to approximately 6% of all women of reproductive age. OCs have been available since the early 1960s, and there is substantial evidence to suggest that no single medication has had such a profound impact on our reproduction and social life than the pill. In the Scandinavian countries, 30–50% of young women have been reported to be using OCs. Its widespread use throughout the world for several decades indicates that women and their doctors have considered that the benefits of OCs outweigh potential side effects. On October 18, 1995, the Committee on Safety of Medicines in the United Kingdom sent a warning to all British doctors and pharmacists about OCs containing desogestrel or gestodene. A similar warning was subsequently distributed by the German and Norwegian health authorities. As these OC types dominate the market in Northern Europe, many gynaecologists, general practitioners, women of reproductive age, different national bodies on drug safety, and people in general have been asking: • ∗ What was the background for these actions? • ∗ How do we interpret the new studies? • ∗ What do we do now concerning prescription of OCs? • ∗ What is the moral of this story?

Journal

ContraceptionElsevier

Published: Mar 1, 1996

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create folders to
organize your research

Export folders, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off